{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:31Z","timestamp":1791849631805,"version":"4.3.4"},"reference-count":30,"publisher":"FapUNIFESP (SciELO)","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are drugs that act by maintaining glycosuria. Recent studies have shown promising effects of these in the treatment of type 2 diabetes mellitus (DM2). However, there may be an increased risk of developing urinary tract infections (UTIs) in patients treated with these. Our study aims to analyze the association between the risk of UTI in patients treated with SGLT2i. A systematic review of the literature was carried out by randomized clinical trials, totalizing at the end of the selection 23 articles that were statistically evaluated. The incidence of UTI was generally demonstrated in articles and in different subgroups: patients on SGLT2i monotherapy or on combination therapy; according to specific comorbidities of each sample or according to the drug used. They noticed an increase in the chance of UTI in the SGLT2i groups compared to the control groups on placebo or other oral antidiabetic agents. This increased chance was found predominantly with the use of Dapagliflozin, Canagliflozin, and Tofogliflozin, regardless of the dosing. Lastly, stands out that the dimension of UTI chances for DM2 patients who use SGLT2i remains to be more strictly determined.<\/jats:p>","DOI":"10.1590\/1806-9282.65.2.246","type":"journal-article","created":{"date-parts":[[2019,3,16]],"date-time":"2019-03-16T16:25:41Z","timestamp":1552753541000},"page":"246-252","source":"Crossref","is-referenced-by-count":23,"title":["Use of sodium-glucose cotransporter-2 inhibitors and urinary tract infections in type 2 diabetes patients: a systematic review"],"prefix":"10.1590","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-6825","authenticated-orcid":false,"given":"Izabela Rodrigues","family":"Figueiredo","sequence":"first","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-0823","authenticated-orcid":false,"given":"Sara Cardoso Paes","family":"Rose","sequence":"additional","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-5282","authenticated-orcid":false,"given":"Nath\u00e1lia Bandeira","family":"Freire","sequence":"additional","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-3140","authenticated-orcid":false,"given":"Marina Stabile","family":"Patroc\u00ednio","sequence":"additional","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5344-9309","authenticated-orcid":false,"given":"Nat\u00e1lia","family":"Pierdon\u00e1","sequence":"additional","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6482-5840","authenticated-orcid":false,"given":"Roberto Jos\u00e9","family":"Bittencourt","sequence":"additional","affiliation":[{"name":"Catholic University of Bras\u00edlia,  Brasil; Catholic University of Bras\u00edlia,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2019,2]]},"reference":[{"key":"ref1","series-title":"Inibidores do co-transportador renal de s\u00f3dio-glicose 2: uma nova classe terap\u00eautica para o controlo de glicemia na diabetes","author":"Dionisio LMC","year":"2015"},{"issue":"1","key":"ref2","first-page":"18","article-title":"Diabete melito: fisiopatologia e tratamento","volume":"5","author":"Marcondes JAM","year":"2003","journal-title":"Rev Fac Ci\u00eanc M\u00e9d Sorocaba."},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2146\/ajhp140168","article-title":"Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes","volume":"72","author":"Vivian EM","year":"2015","journal-title":"Am J Health Syst Pharm."},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/dme.12624","article-title":"Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial","volume":"38","author":"Bailey CJ","year":"2014","journal-title":"Diabet Med."},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder J","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder J","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato S","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, study","volume":"37","author":"Jabbour SA","year":"2014","journal-title":"Diabetes Care."},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/jgs.12881","article-title":"Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"62","author":"Leiter LA","year":"2014","journal-title":"J Am Geriatr Soc."},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck MA","year":"2011","journal-title":"Diabetes Care."},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock J","year":"2012","journal-title":"Diabetes Care."},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding JP","year":"2012","journal-title":"Ann Intern Med."},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/dom.12187","article-title":"Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years","volume":"16","author":"Wilding JP","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study","volume":"36","author":"Ji L","year":"2014","journal-title":"Clin Ther."},{"issue":"9896","key":"ref15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu WT","year":"2013","journal-title":"Lancet."},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","article-title":"Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study","volume":"15","author":"Inagaki N","year":"2014","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc14-1237","article-title":"Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes","volume":"38","author":"Neal B","year":"2014","journal-title":"Diabetes Care."},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.01.2720","article-title":"Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"126","author":"Nicolle LE","year":"2014","journal-title":"Postgrad Med."},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1185\/03007995.2012.689956","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study","volume":"28","author":"Nicolle LE","year":"2012","journal-title":"Curr Med Res Opin."},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes","volume":"59","author":"Cherney D","year":"2016","journal-title":"Diabetologia."},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini E","year":"2013","journal-title":"Diabetes Care."},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Kim G4, Woerle HJ4, Broedl UC4; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le M","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock J","year":"2014","journal-title":"Diabetes Care."},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/dom.12185","article-title":"Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia","volume":"15","author":"Rosenstock J","year":"2013","journal-title":"Diabetes Obes Metab."},{"issue":"22","key":"ref25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","journal-title":"N Engl J Med."},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/dom.12538","article-title":"A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus","volume":"17","author":"Ikeda S","year":"2015","journal-title":"Diabetes Obes Metab."},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock J","year":"2012","journal-title":"Diabetes Care."},{"key":"ref28","doi-asserted-by":"crossref","first-page":"6573215","DOI":"10.1155\/2016\/6573215","article-title":"Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycemia in Kuwait","volume":"2016","author":"Sewify M","year":"2016","journal-title":"J Diabetes Res."},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.numecd.2016.07.006","article-title":"Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors","volume":"26","author":"Rizzi M","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings S","year":"2014","journal-title":"Diabetes Res Clin Pract."}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v65n2\/1806-9282-ramb-65-02-0246.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:12:35Z","timestamp":1581441155000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302019000200246&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["S0104-42302019000200246"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.65.2.246","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"value":"1806-9282","type":"electronic"},{"value":"0104-4230","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}